Supports Phase 3 readiness of AP-SA02

Non-dilutive DoD funding totals $28.7M to date

LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $2.5 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The award, which now totals $28.7 million, supports the development of Armata's lead clinical candidate AP-SA02, for adjunct treatment of complicated Staphylococcus aureus ("S. aureus") bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA"). The additional $2.5 million is intended to fund key activities to support Phase 3 readiness of AP-SA02.